Driehaus Capital RLMD Position
Active5-Fund ConvergenceDriehaus Capital increased their position in RELMADA THERAPEUTICS, INC. (RLMD) in Q4 2025, holding $9.1M worth of shares across 1,880,006 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
RLMD is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for NDV-01 (sustained-release gemcitabine-docetaxel) in 1263 days (Sep 30, 2029), making the timing of Driehaus's position particularly relevant.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Full company profile →Short Interest
5.1%
1.2 days to cover
Driehaus Capital RLMD Position History
Frequently Asked Questions
Does Driehaus Capital own RLMD?
Yes. As of Q4 2025, Driehaus Capital holds 1,880,006 shares of RELMADA THERAPEUTICS, INC. (RLMD) valued at $9.1M. This data comes from their SEC 13F filing.
How many hedge funds own RLMD?
5 specialist biotech hedge funds currently hold RLMD, including OrbiMed Advisors, Deep Track Capital, RTW Investments and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy RLMD?
Driehaus Capital's position in RLMD was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's RLMD position increasing or decreasing?
Driehaus Capital increased their RLMD position in the most recent quarter, adding 1,140,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RLMDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →